- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 330 - Related articles - BL Direct - All 7 versions
HE Scholtz, SG Pretorius, DH Wessels, RHA … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: This single-dose, double- blind, randomised,
parallel-group study evaluated the reproducibility in systemic exposure and
glucodynamic effect of insulin glargine, NPH insulin (NPH) and insulin ... Cited by 61 - Related articles - BL Direct - All 3 versions
RG Bretzel, U Nuber, W Landgraf, DR Owens, … - The Lancet, 2008 - Elsevier In the 44-week, parallel, open study that was undertaken in 69 study sites
across Europe and Australia, 418 patients with type 2 diabetes mellitus that was
inadequately controlled by oral hypoglycaemic agents were randomly assigned ... Cited by 50 - Related articles - All 24 versions
SCL Gough - Diabetes research and clinical practice, 2007 - Elsevier A recent meta-analysis evaluated trials of the rapid-acting analogues insulin
lispro and insulin aspart, performed before the introduction of the basal
analogues, insulin glargine and insulin detemir. This article reviews the ... Cited by 43 - Related articles - All 21 versions
AH Barnett, J Burger, D Johns, R Brodows, … - Clinical therapeutics, 2007 - Elsevier Methods: This multinational, randomized, open-label, crossover noninferiority
study compared the efficacy of exenatide 10 pg BID and insulin glargine QD
(titrated targeting a fasting serum glucose (FSG) level ≤5.6 mmol/L) in ... Cited by 39 - Related articles - All 3 versions
HC Gerstein, JF Yale, SB Harris, M Issa, JA … - DIABETIC MEDICINE-CHICHESTER-, 2006 - interscience.wiley.com Methods Consenting adults aged 18–80 years with Type 2 diabetes for at least 6
months, HbA 1c of 7.5–11%, and on 0, 1 or 2 oral agents, were randomized to
one of two therapeutic approaches for 24 weeks: evening insulin glargine ... Cited by 31 - Related articles - BL Direct - All 5 versions
L Pogach, M Engelgau, D Aron - JAMA, 2007 - Am Med Assoc Despite increasing recognition of the effect of diabetes on the health of the US
population, there has been only modest improvement in glycemic control among
most demographic groups from the 1990s to the early 2000s regardless of ... Cited by 28 - Related articles - BL Direct - All 4 versions
P Mullins, P Sharplin, H Yki-Jarvinen, MC … - Clinical therapeutics, 2007 - Elsevier Methods: Patient-level data from all randomized Phase III/IV clinical trials
sponsored by the manufacturer of glargine that compared glargine and NPH and
were available in May 2004 were included in the model. In addition, ... Cited by 26 - Related articles - All 3 versions
- ►diabetesjournals.org [PDF] JM Woolderink, AJ van Loon, F Storms, L de … - Diabetes Care, 2005 - Am Diabetes Assoc Glial cell line–derived neurotrophic factor (GDNF) belongs to the neu-
rotrophic factor family. GDNF functions are not restricted to neurons but are
also implicated in glial cell develop- ment (1). We observed high ... Cited by 24 - Related articles - BL Direct - All 5 versions
D Raccah, RG Bretzel, D Owens, M Riddle - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 22 - Related articles - BL Direct - All 3 versions
